Scotiabank周三重申了对INmune Bio Inc. (NASDAQ:INMB)的行业跑赢大盘评级,目标价保持在22.00美元。这一评级背景是该生物技术公司正在进行XPro的2期临床试验,XPro是一种针对早期阿尔茨海默病 (AD)的TNF抑制剂。根据最新的盲法试验测量,试验的主要终点EMACC与关键次要结果CDR在统计学上存在相关性。
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BTIG重申了对INmune Bio Inc. (NASDAQ: INMB)的买入评级和21.00美元的目标价,强调了该公司在阿尔茨海默病(AD)药物开发方面的创新方法。 INmune Bio目前正通过一项比该领域典型研究更短且可能规模更小的2期试验来验证其抗炎症治疗XPro对AD的效果。 该试验的EMACC终点与CDR-SB黄金标准显示出相关性,尽管后者通常被认为对变化不敏感。 该公司指出,EM ...
Miami Dolphins Linked to Trading for Pittsburgh Steelers’ QB as Tua Tagovailoa ‘Stopgap’ These 10 restaurants are considered the 'best of the best' in the US, says Tripadvisor Rockies' Charlie ...
XPRO India Ltd share price was up by -0.42% from the previous closing price of ₹1,143.45. Who are peers of XPRO India Ltd? The peers of XPRO India Ltd are Inox India Ltd, EPL Ltd, Garware Hi ...
Compared with ball heads, the Manfrotto XPRO Geared 3-way head stays put after being adjusted. While ball heads enable the speed and ease of making adjustments in all three tilt, pan and swivel ...